Creatinine Clinical Chemistry Study Notes

CREATININE IN CLINICAL CHEMISTRY

Overview of Creatinine

  • Creatinine: A key renal function test used to detect kidney disease through serum and urine analysis.

    • Other tests used to evaluate kidney function include:

    • Urea Nitrogen (BUN)

    • Glomerular Filtration Rate (GFR)

    • Cystatin C

Formation and Elimination

  • Source of Creatinine:

    • Formed from creatine and creatine phosphate in muscle tissue.

    • Excreted into plasma at a constant rate, proportional to muscle mass.

    • Reference Range: Varies with age and gender;

      • Males typically have higher creatinine levels due to greater muscle mass.

  • Clearance Measurement:

    • Creatinine clearance from plasma by the kidneys is a measure of GFR.

    • Relationship to GFR:

    • Plasma creatinine is inversely related to GFR.

    • As GFR decreases, plasma creatinine levels increase, indicating reduced renal function.

Clinical Significance of Plasma Creatinine

  • What Plasma Creatinine Reflects:

    • Muscle Mass: Relatively stable over time.

    • Rate of Creatine Turnover: Stable.

    • Renal Function.

  • Increased Serum Creatinine:

    • Indicates decreased renal function (lowered GFR).

    • May not elevate until kidney function is reduced by 50%:

      • For every 50% reduction in GFR, creatinine levels double.

  • Decreased Serum Creatinine:

    • Reflects decreased muscle mass or muscle atrophy.

    • Positive pregnancy effect: Increased GFR leads to lower serum creatinine concentrations.

Creatinine Measurement Techniques

  • Purpose of Measurement:

    • Assess kidney function (not sensitive enough to detect mild dysfunction).

    • Determine the severity of kidney disease.

    • Monitor progression of kidney disease.

  • Urine Creatinine:

    • Typically stable on a day-to-day basis, making it useful for verifying completeness of 24-hour urine samples.

    • Other urine constituents can be quantified as a ratio to creatinine (e.g., albumin/creatinine ratio in random urine).

Measurement Variables
  • Types of Samples:

    • Plasma, serum, urine

    • Urine samples should be refrigerated if testing is delayed.

  • General Interferences:

    • Hemolysis: Affects Jaffe method.

    • Icterus (jaundice): Introduces negative bias.

    • Lipemia: Affects several methods; inhibits optical readings.

Assay Methods for Creatinine
  • Jaffe Reaction:

    • Utilizes alkaline picrate to form a red-orange chromagen.

    • Non-specific method: Numerous interferences.

    • Can be performed as a kinetic reaction, which has fewer interferences compared to endpoint reactions.

  • Enzymatic Methods:

    • Involve coupled reactions.

  • Dynamic Range for Measurement:

    • Serum/Plasma: 8.84 – 2210 µmol/L

    • Urine: 0.88 – 35.36 mmol/L

    • For samples exceeding the high end of the analytical range, dilute with saline and re-analyze, then multiply results by two.

Endpoint vs Kinetic Reactions

  • End-Point Assays:

    • Measure absorbance at completion.

    • Can use:

    • Single standard,

    • Standard curve,

    • Molar absorptivity methods for concentration calculation.

    • Enzyme analyses not performed as end-point reactions.

  • Kinetic Reactions:

    • Do not reach completion; absorbances are measured at intervals over time.

  • Phases in Reactions:

    • Lag Phase: Reactants begin to interact.

    • Reacting Phase: Product formation occurs.

    • Reagent Depletion Phase: Reactants dwindle as the reaction progresses.

Analytical Methods for Creatinine (Table 12-6 Summary)
  • Chemical Methods Based on Jaffe Reaction:

    • Jaffe reaction: creatinine reacts with picrate to form a colored complex.

    • Jaffe-kinetic: optimized to avoid interference of non-creatinine chromogens.

    • Jaffe methods with and without adsorbents to improve specificity.

  • Enzymatic Methods:

    • Involve steps that convert creatinine into other bi-products measured by changes in absorbance.

  • Other Methods:

    • Isotope dilution mass spectrometry is a highly specific reference method for quantification.

Beckman Creatinine Methodology
  • Involves introducing a precise volume of sample into the Jaffe reagent.

  • Detectors measure absorbance increases at 520 nm and 560 nm, with timing changes to determine creatinine concentration.

Calibration Procedures

  • Calibration Ranges:

    • Synchronization AQUA Cal 1 & 2: Must be calibrated every 48 hours or following maintenance/troubleshooting.

  • DXC Calibration:

    • Involves checks for accuracy, precision, and sensitivity with previous standards thrown out for highest and lowest readings.

    • Acceptability Parameters: Focus on range, accuracy, precision (back-to-back), and span sensitivity.

Quality Control in Measurements
  • Running Quality Controls:

    • At least one set per shift, with special checks post maintenance or lot changes.

  • Common QC Issues:

    • Improper temperature storage for control samples can cause failures.

    • Errors must be identified as calibration issues or QC only concerns.

Sources of Error in Creatinine Assays
  • Different components can bias results, affecting accuracy:

    • Jaffe Assay: Affected by ascorbate, uric acid, glucose, ketones, and cephalosporins.

    • Enzymatic Assays: Affected by ascorbate (when associated with peroxidase) and certain drugs like dopamine and lidocaine.

Reference Ranges for Creatinine

  • Serum/Plasma:

    • Children: 27-62 µmol/L

    • Adults: Males 80-115 µmol/L; Females 53-97 µmol/L.

  • Critical Levels: Values greater than 600 µmol/L are deemed critical.

  • 24-hour Urine Excretion:

    • Males: 7.1-17.7 mmol/day

    • Females: 5.3-15.9 mmol/day

    • Random urine does not have a standardized reference range.

References

  • Beckman Coulter Instructions For Use: UniCel® DXC Synchron Clinical Systems, Volume 1, 2008.

  • Beckman Coulter In-Lab Training Manual: UniCel® DXC 800, 2005.

  • Clinical Chemistry: Principles, Techniques, and Correlations, 8th Edition. Bishop, M.L.; Fody, E.P.; Schoeff, Wolters Kluwer 2018.